Aug 22, 2023 · Regulatory information

Cantargia publishes half year report

Cantargia AB’s (”Cantargia”) half year report for the period January until June 2023 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.

Significant events in the second quarter

At AACR 2023, promising efficacy data was presented for nadunolimab with chemotherapy in pancreatic cancer (PDAC), in particular in patients with high levels of IL1RAP.
Plans were announced for a randomized controlled clinical phase IIb trial to evaluate nadunolimab with chemotherapy in additional PDAC patients.
At ASCO 2023, promising efficacy was presented for nadunolimab with chemotherapy also in non-small cell lung cancer (NSCLC), including two complete responses.
Enrollment to the CANFOUR trial was completed; favorable safety was reported for nadunolimab with carboplatin/pemetrexed in non-squamous NSCLC patients.

Significant events after the end of the period

An application to start a phase I clinical trial for CAN10, which was submitted during the quarter, was approved by regulatory authorities.
In response to the oppositions on Cantargia’s patent EP3293202, the European Patent Office (EPO) ruled that the patent should remain in force with an updated patent scope.

Financial information

First half 2023 (1 Jan 2023 – 30 Jun 2023)

Net sales: SEK 0.0 M (0.0)
Operating loss: SEK -140.2 M (-217.6)
Loss after tax: SEK -132.3 M (-210.7)
Loss per share: before and after dilution, SEK -0.79 (-2.10)
Equity/assets ratio: 76 (83) per cent
Cash and cash equivalents: SEK 158.9 M (114.1)
Short-term investments: SEK 128.3 M (236.1)

Second quarter 2023 (1 Apr 2023 – 30 Jun 2023)

Net sales: SEK 0 M (0)
Operating loss: SEK -62.6 M (-96.0)
Loss after tax: SEK -56.4 M (-93.3)
Loss per share, before and after dilution: SEK -0.34 (-0.93)

In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on August 22, at 3:00 p.m. CEST, where Göran Forsberg, CEO, and Cantargia’s new CFO, Patrik Renblad, will present Cantargia and comment on the interim report, followed by a Q&A-session.

If you wish to participate via webcast, please use the link below. Via the webcast you are able to ask written questions. Webcast: https://ir.financialhearings.com/cantargia-q2-2023

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://conference.financialhearings.com/teleconference/?id=200932

The webcast will also be available on demand on Cantargia’s corporate website: http://www.cantargia.com

About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. The main program, the antibody nadunolimab (CAN04), is being studied clinically primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive interim data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia’s second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.